Smoking is the most important modifiable cardiovascular risk factor in young women. The aim of this study was to investigate whether tobacco use influences physiological changes in endothelial function during the menstrual cycle. Methods and Results: Flow-mediated dilation (FMD) and nitro-mediated dilation (NMD) were assessed in healthy smoking and non-smoking women, by high-resolution ultrasound at 3 time points during the menstrual cycle: at menstruation, in the mid-follicular phase, and in the mid-luteal phase. A total of 25 women (12 nonsmokers, 13 smokers) completed the study protocol. FMD did not show differences between smoking and nonsmoking women at menstruation and the mid-follicular phase. At the mid-luteal phase, however, FMD was significantly reduced in smoking when compared with non-smoking women. NMD did not differ between smoking and non-smoking women, nor between the different cycle phases. Conclusions: In healthy women, smoking eliminates the physiological amelioration of endothelial function during the menstrual cycle. This study underlines the importance of an exact description of menstrual cycle phase and smoking status in studies investigating endothelial function in premenopausal women. (Circ J 2009; 73: 568 -572) 
hroughout the world, cardiovascular diseases are the greatest single cause of mortality among women, with a share of one-third of all deaths. Owing to the proven beneficial properties of endogenous estrogens, until advanced age women normally enjoy greater protection against cardiovascular diseases than do their male counterparts. 1 Even though myocardial infarction (MI) in young women is rare, increasing incidence over time has been described; in fact, 5% of MI occur in premenopausal women. 2 One major anti-atherosclerotic property of estrogens is their beneficial effect on endothelial function. It is well established that estrogens ameliorate in-vitro and in-vivo endothelial function, primarily by increasing the bioavailability of endothelium-derived nitric oxide. 3 Several studies have suggested that endothelial function changes during the menstrual cycle concur with changing hormonal levels: depressed endothelial function has been determined during the menstrual phase, the cycle phase with lowest estrogen and progesterone levels. [4] [5] [6] Interestingly, the incidence of MI and variant angina in premenopausal women also evidently manifests itself increasingly during this phase of the menstrual cycle. 5, 7 Smoking is the most important modifiable risk factor for atherosclerosis in young women. Some evidence has been published that chronic smoking plays a critical role in the development of premature coronary artery disease: eg, 70% of women younger than 45 years with coronary artery disease are current smokers. 8 Although nicotine abuse is harmful at any age, the increase in the relative risk of coronary events in young women appears to be particularly augmented, especially given the context of their baseline low risk. The biological mechanisms linking smoking and atherogenesis are complex and not fully understood. In addition to inflammation, potential mechanisms by which smoking increases the risk of cardiovascular diseases include systemic hemostatic and coagulation disturbances, lipid abnormalities, increased oxidative stress, and vascular endothelial dysfunction. [9] [10] [11] [12] It has been suggested that chronic smoking in young women influences the physiological hormonal cycle and modulates levels of sex steroids. [13] [14] [15] Until now, it is unclear whether smoking in this context also modulates physiological changes in endothelial function during the menstrual cycle. In the present study, we therefore investigated whether nicotine abuse influences endothelial-dependent vasodilation of the brachial artery in the course of the menstrual cycle in young, healthy women without other cardiovascular risk factors.
Methods

Study Population
The study protocol was reflected in a priori approval by the institution's Human Research Committee. Non-smoking and smoking women aged between 25 and 35 years were recruited by press advertisement. A total of 646 responded, and interviews were conducted with these women. Subjects 
Chronic Smoking Prevents Amelioration of Endothelial
Function in the Course of the Menstrual Cycle with chronic diseases or known cardiovascular risk factors, such as high blood cholesterol, diabetes, arterial hypertension, and obesity, were excluded. All women had regular menstrual cycles and had not taken medication for more than 3 months before study entry. The admitted non-smoking women had never smoked and had lived in a non-smoking household. Admitted smoking women were required to have smoked at least 15 cigarettes/day for at least 1 pack year. A total of 122 women were invited for preliminary examinations during the luteal phase at day M-5 (day 1 is the first day of menstrual bleeding [M] of the expected following menstrual bleeding) of the previous menstrual cycle. All values for clinical parameters were required to lie within the normal range to allow study inclusion: lipid profile, blood pressure, body mass index, as well as routine internal and endocrine parameters. Serum progesterone was required to be >18 nmol/L. A total of 45 female subjects entered the study after providing written consent. During the study protocol, 6 women were excluded because of insufficient ultrasound image quality, 9 owing to cycle irregularities, and 5 because of acute infections; 25 volunteers finally finished the study protocol.
Study Design
At 08.00 h on each day of examination, after a 12-h overnight fast that included prohibition of smoking, the 25 volunteers underwent 3 clinical examinations during the subsequent menstrual cycle: during the menstrual (M+3; day 3 after first day of menstrual bleeding), mid-follicular (M+7; day 7 after first day of menstrual bleeding), and midluteal (M-5) phases. Blood samples were collected from the antecubital vein, centrifuged, and stored at -70°C until chemical analysis. Endothelial function was measured by high-resolution vascular ultrasound. The investigated menstrual cycle was required to be of normal length without bleeding irregularities, and at M-5 the minimum limit for progesterone was 18 nmol/L, otherwise the volunteer was excluded.
Measurement of Flow-Mediated Dilation (FMD) and Nnitro-Mediated Dilation (NMD)
Endothelial function was measured by high-resolution vascular ultrasound with a 13-MHz linear-array transducer (Sonoline Antares, Siemens, Germany), as recently described. 16 We assessed endothelium-dependent FMD by measuring the change in the brachial artery diameter during reactive hyperemia after cuff occlusion of the forearm for 5 min, according to established guidelines. 17 The nature of the stimulus and conditions for measurement of FMD were chosen to obtain a nitric-oxide-dependent response after a brief period of shear stress in the brachial artery. 18 We obtained longitudinal images of the brachial artery proximal to the antecubital fossa. To improve the accuracy and reproducibility of the test, the authors designed a special device to secure the ultrasound probe at a fixed location on the brachial artery during the entire testing period. Changes in arterial diameter were measured every 15 s for up to 2 min. FMD was defined as the maximum percentage change in diameter compared with the baseline measurement. Endothelium-independent vasodilation (NMD) was measured after sublingual application of nitroglycerin spray (0.4 mg). The increase in diameter of the brachial artery was measured from 1 to 6 min, and NMD was defined as the maximum percentage change in diameter compared with the baseline measurement. Ultrasound images were digitized online and saved. Two different investigators who were unaware of subject treatment conducted offline analyses of diameter changes (Tom Tec Imaging Systems, Germany).
Statistical Analysis
Values are presented as mean ± standard deviation, unless otherwise stated. All statistical tests were 2-sided (level of significance, 0.05). Values with normal distribution were analyzed with parametric tests. For comparisons of clinical parameters, which are not normally distributed, non-paramet- 
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ric rank sum tests were used (paired Wilcoxon test, MannWhitney test). Linear regression analysis were performed for delta changes in FMD (delta 1= M+7-M+3 and delta 2 =M-5-M+3) and adjusted for age, glucose, testosterone and triglycerides. Correlations are given by the Spearman rank correlation coefficient. Statistical analysis was performed using SPSS, release 15.0 (Chicago, IL, USA).
Results
A total of 25 women (12 non-smokers, 13 smokers) with ovulatory menstrual cycles completed the study protocol. Baseline characteristics of the study group are shown in Table 1 . Smoking women were slightly older than nonsmoking (34.2±1.2 vs 30.3±3.2 years, P<0.05). Although the results were within the normal range, we found significantly higher glucose, triglyceride and testosterone concentrations in the smoking women than in the non-smoking women during the preliminary examination. In the investigated menstrual cycle, concentrations of sex steroids demonstrated the typical cyclic pattern with significantly higher levels of estradiol and progesterone at the mid-luteal phase than in the menstrual and mid-follicular phases. In the mid-luteal phase, estradiol levels were lower in smoking women (495± 105 vs 668±176 pg/ml, P<0.05) (Figure 1) . FMD levels showed wide inter-individual distribution, from 3.33% to 20.83%. There were no differences in FMD between smoking and non-smoking women at menstruation or in the mid-follicular phase. In the mid-luteal phase, FMD was lower in smoking women (7.1±3.0% vs 10.7±4.5%, P<0.05) (delta changes of FMD are shown in Figure 2) . FMD in smoking women showed a trend towards lower values in the midluteal phase than during menstruation. In contrast, FMD in non-smoking women was slightly higher at the mid-luteal phase than in the menstrual phase. No significant correlations between estradiol level and FMD were found at various cycle phases in either non-smoking or smoking women. Adjustment of FMD values in the linear regression analysis for age, glucose, triglycerides, and testosterone did not disclose an influence of these variables. NMD did not differ between smoking and non-smoking women, or between the various cycle phases (Figure 3) . All results of the intervention study are presented in detail in Table 2 . Intra-and interobserver correlation coefficients were 0.99 and 0.96, respectively. .05 non-smokers vs smokers in the mid-luteal phase. Non-smokers (n=12); smokers (n=13). FMD, flow-mediated dilation; NMD, nitro-mediated dilation; FMDbase, diameter of the brachial artery before hyperemic stimulus; FMDmax (mm); maximum diameter of the brachial artery after hyperemic stimulus; FMDmax (%), maximum percentage change in brachial artery diameter compared with baseline measurement after hyperemic stimulus; NMDbase, diameter of the brachial artery before application of nitroglycerine spray; NMDmax (mm), maximum diameter of the brachial artery after sublingual application of nitroglycerine spray; NMDmax (%), maximum percentage change in brachial artery diameter compared with baseline measurement after sublingual application of nitroglycerine spray.
Discussion
The main result of our study is that endothelial function is significantly impaired in smoking women in the mid-luteal phase, when compared with non-smoking women, whereas in the menstrual phase endothelial function is nearly identical in the 2 groups. Reduced FMD values in smokers in the mid-luteal phase compared with non-smokers suggest that physiological hormonal changes are of importance. Indeed, the increase in the estradiol level in the course of the menstrual cycle was lower in smoking women, which may serve as a partial explanation for the difference in endothelial function in the mid-luteal phase.
Physiological changes in endothelial function in premenopausal women have been described previously. Some investigators have shown that FMD increased with rising levels of estradiol during the follicular phase, declined after ovulation, and then rose again during the luteal phase. [4] [5] [6] In our study, we similarly determined a trend towards increasing endothelial function in the course of the menstrual cycle in non-smoking women. FMD accordingly peaked in our study during the cycle phase in which the estradiol level was highest.
It is well known that cigarette smoking, and even passive smoking, is sufficient to impair endothelial function in healthy adults, which is consistent with findings on the early stages of endothelial dysfunction. 10, 11, [19] [20] [21] Celermajer et al found an inverse relationship between FMD and cigarette exposure in 200 asymptomatic young adults. 19 Although, as discussed, hormonal cycle-dependent changes of endothelial function are relevant in premenopausal women, most clinical studies on the effects of smoking on endothelialdependent vasodilation have not considered the menstrual cycle phases in young women. Garcia-Fernandez et al demonstrated that the acute effect of smoking 1 cigarette leads to pronounced depression of FMD, without differences between menstruation and follicular phases. 22 Interestingly, our data show that detrimental effects on endothelial function induced by chronic nicotine abuse become apparent only with rising estradiol levels in healthy young women without other cardiovascular risk factors. The fact that the increase in estradiol during the menstrual cycle was lower in smoking than in non-smoking women may account for this difference in endothelial function between the 2 groups.
Several previous studies have discussed the possibility that chronic nicotine abuse may reduce estrogen production, [13] [14] [15] and anti-estrogenic properties of nicotine via interference with hepatic estrogen metabolism have been discussed as the underlying mechanism. 23 It has been shown that smoking leads to increased formation of 2-hydroxylated estrogen metabolites, which have lower estrogenic activity. 24 However, the data are not uniform; others have found no difference in the endogenous serum estradiol level of premenopausal smokers and non-smokers. 25 
Study Limitations
Because of our small sample size, the smoking women were somewhat older than the non-smokers. It cannot be ruled out that the older age of the smoking women contributed to worse endothelial function. However, because we found no difference between the 2 groups in FMD in the menstrual phase, the modulating role of age is unlikely. In line with other studies, some baseline plasma concentrations, such as glucose, triglyceride and testosterone, were slightly greater in smoking than in non-smoking women. [26] [27] [28] [29] Because these differences were small and within the normal range, the influence of smoking-dependent effects on endothelial function during the menstrual cycle is likewise improbable. Accordingly, adjustment of FMD values in the linear regression analysis did not show an influence of these parameters on our study results.
Taken together, our data indicate that smoking interacts with physiological hormonal regulation in premenopausal women, and that the detrimental effects of smoking on endothelial function become more relevant with high levels of sex steroids. This study, furthermore, demonstrates the importance of assuring exact description of menstrual cycle phase, together with tobacco use, in studies that investigate premenopausal women.
